Claire Rimes-Stigare
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Claire Rimes-Stigare has a total of 22 co-authors. Here are the top co-authors by number of shared publications:
- Max Bell
Department of Perioperative Medicine and Intensive Care, Karolinska University Hospital, Stockholm, Sweden
4 shared publications - Johan Mårtensson
Department of Physiology and Pharmacology, Section of Anaesthesia and Intensive Care, Karolinska Institutet, Stockholm, Sweden
3 shared publications - Claes-Roland Martling
Section of Anaesthesia and Intensive Care Medicine, Department of Physiology and Pharmacology, Karolinska Institutet, Solna, Sweden
2 shared publications - Matteo Bottai
Division of Biostatistics Institute of Environmental Medicine Karolinska Institutet
2 shared publications - Paolo Frumento
Unit of Biostatistics, Institute of Environmental Medicine (IMM), and Karolinska Institute, Stockholm, Sweden.
2 shared publications A. Awad
Department of Anaesthesiology and Intensive Care Karolinska University Hospital Stockholm Sweden
1 shared publication
Latest Publications
- Open Access
- 28 March 2024
- Published by Elsevier in British Journal of Anaesthesia
- Vol. 132 (6) , 1238-1247
Advanced chronic kidney disease after surgery and the contribution of acute kidney disease: a national observational cohort study
- 28 March 2024
- Published by Elsevier in British Journal of Anaesthesia
- Vol. 132 (6) , 1238-1247
Open AccessAdvanced chronic kidney disease after surgery and the contribution of acute kidney disease: a national observational cohort study
- 1 August 2021
- Published by Elsevier in Journal of Critical Care
- Vol. 64, 125-130
Continuous renal replacement therapy in intensive care patients with COVID-19; survival and renal recovery
- 1 August 2021
- Published by Elsevier in Journal of Critical Care
- Vol. 64, 125-130
Continuous renal replacement therapy in intensive care patients with COVID-19; survival and renal recovery
- Open Access
- 27 September 2018
- Published by Wiley in Critical Care Research and Practice
- Vol. 2018, 1-8
Creatinine- and Cystatin C-Based Incidence of Chronic Kidney Disease and Acute Kidney Disease in AKI Survivors
Background. Renal dysfunction after acute kidney injury (AKI) is common, potentially modifiable, but poorly understood. Acute kidney disease (AKD) describes renal dysfunction 7 to 90 days after AKI and is determined by percentage change in creatinine from baseline. Chronic kidney disease (CKD) is defined as the estimated glomerular filtration rate (eGFR) less than 60 ml/min/1.73 m2 persisting for more than 90 days. We compared CKD incidence using both creatinine- and cystatin C-based GFR with AKD incidence at 90 days in AKI survivors. Methods. A prospective cohort study was conducted in a Swedish intensive care unit (ICU) between 2008 and 2010. We included AKI patients alive at 90 days. We excluded patients 100 years, death before follow-up, CKD prior to admission, and follow-up before 60 days or beyond 270 days. Creatinine and cystatin C were measured at 90 days and converted to eGFR (mL/min/1.73 m2). Results. We included 274 patients. At 90-day follow-up, the median creatinine eGFR (MDRD) was 81.6 (IQR 58.6–106.8) and median cystatin C eGFR was 51.5 (IQR 35.8–70.7). The incidence of CKD (eGFR < 60) was 25.8% based on creatinine but 63.7% using cystatin C estimates. AKD was present in 47 patients (18.9%). Age, discharge cystatin C, creatinine at discharge, and female gender predicted creatinine-defined CKD at follow-up. Age, discharge cystatin C, CRRT on ICU, and diabetes were associated with cystatin C-based CKD. Conclusions. In AKI survivors followed up at 3 months, CKD criteria were met in a quarter of patients using creatinine and in two-thirds using cystatin C eGFR. Less than one-fifth of patients fulfilled AKD criteria. The application of AKD criteria may underestimate renal dysfunction in AKI survivors.
- 27 September 2018
- Published by Wiley in Critical Care Research and Practice
- Vol. 2018, 1-8
Open AccessCreatinine- and Cystatin C-Based Incidence of Chronic Kidney Disease and Acute Kidney Disease in AKI Survivors
Background. Renal dysfunction after acute kidney injury (AKI) is common, potentially modifiable, but poorly understood. Acute kidney disease (AKD) describes renal dysfunction 7 to 90 days after AKI and is determined by percentage change in creatinine from baseline. Chronic kidney disease (CKD) is defined as the estimated glomerular filtration rate (eGFR) less than 60 ml/min/1.73 m2 persisting for more than 90 days. We compared CKD incidence using both creatinine- and cystatin C-based GFR with AKD incidence at 90 days in AKI survivors. Methods. A prospective cohort study was conducted in a Swedish intensive care unit (ICU) between 2008 and 2010. We included AKI patients alive at 90 days. We excluded patients 100 years, death before follow-up, CKD prior to admission, and follow-up before 60 days or beyond 270 days. Creatinine and cystatin C were measured at 90 days and converted to eGFR (mL/min/1.73 m2). Results. We included 274 patients. At 90-day follow-up, the median creatinine eGFR (MDRD) was 81.6 (IQR 58.6–106.8) and median cystatin C eGFR was 51.5 (IQR 35.8–70.7). The incidence of CKD (eGFR < 60) was 25.8% based on creatinine but 63.7% using cystatin C estimates. AKD was present in 47 patients (18.9%). Age, discharge cystatin C, creatinine at discharge, and female gender predicted creatinine-defined CKD at follow-up. Age, discharge cystatin C, CRRT on ICU, and diabetes were associated with cystatin C-based CKD. Conclusions. In AKI survivors followed up at 3 months, CKD criteria were met in a quarter of patients using creatinine and in two-thirds using cystatin C eGFR. Less than one-fifth of patients fulfilled AKD criteria. The application of AKD criteria may underestimate renal dysfunction in AKI survivors.
- Open Access
- 1 December 2015
- Published by Springer Nature in Critical Care
- Vol. 19 (1) , 1-12
Long-term mortality and risk factors for development of end-stage renal disease in critically ill patients with and without chronic kidney disease
Introduction: Prevalence of chronic kidney disease (CKD) amongst intensive care unit (ICU) admissions is rising. How mortality and risk of end-stage renal disease (ESRD) differs between those with and without CKD and with acute kidney injury (AKI) is unclear. Determining factors that increase the risk of ESRD is essential to optimise treatment, identify patients requiring nephrological surveillance and for quantification of dialysis provision. Method: This cohort study used the Swedish intensive care register 2005–2011 consisting of 130,134 adult patients. Incomplete cases were excluded (26,771). Patients were classified (using diagnostic and intervention codes as well as admission creatinine values) into the following groups: ESRD, CKD, AKI, acute-on-chronic disease (AoC) or no renal dysfunction (control). Primary outcome was all-cause mortality. Secondary outcome was ESRD incidence. Results: Of 103,363 patients 4,192 had pre-existing CKD; 1389 had ESRD; 5273 developed AKI and 998 CKD patients developed AoC. One-year mortality was greatest in AoC patients (54 %) followed by AKI (48.7 %), CKD (47.6 %) and ESRD (40.3 %) (P < 0.001). Five-year mortality was highest for the CKD and AoC groups (71.3 % and 68.2 %, respectively) followed by AKI (61.8 %) and ESRD (62.9 %) (P < 0.001). ESRD incidence was greatest in the AoC and CKD groups (adjusted incidence rate ratio (IRR) 259 (95 % confidence interval (CI) 156.9–429.1) and 96.4, (95 % CI 59.7–155.6) respectively) and elevated in AKI patients compared with controls (adjusted IRR 24 (95 % CI 3.9–42.0); P < 0.001). Risk factors independently associated with ESRD in 1-year survivors were, according to relative risk ratio, AoC (356; 95 % CI 69.9–1811), CKD (267; 95 % CI 55.1–1280), AKI (30; 95 % CI 5.98–154) and presence of elevated admission serum potassium (4.6; 95 % CI 1.30–16.40) (P < 0.001). Conclusions: Pre-ICU renal disease significantly increases risk of death compared with controls. Subjects with AoC disease had extreme risk of developing ESRD. All patients with CKD who survive critical care should receive a nephrology referral. Trial registration: Clinical trials registration number: NCT02424747 April 20th 2015.
- 1 December 2015
- Published by Springer Nature in Critical Care
- Vol. 19 (1) , 1-12
Open AccessLong-term mortality and risk factors for development of end-stage renal disease in critically ill patients with and without chronic kidney disease
Introduction: Prevalence of chronic kidney disease (CKD) amongst intensive care unit (ICU) admissions is rising. How mortality and risk of end-stage renal disease (ESRD) differs between those with and without CKD and with acute kidney injury (AKI) is unclear. Determining factors that increase the risk of ESRD is essential to optimise treatment, identify patients requiring nephrological surveillance and for quantification of dialysis provision. Method: This cohort study used the Swedish intensive care register 2005–2011 consisting of 130,134 adult patients. Incomplete cases were excluded (26,771). Patients were classified (using diagnostic and intervention codes as well as admission creatinine values) into the following groups: ESRD, CKD, AKI, acute-on-chronic disease (AoC) or no renal dysfunction (control). Primary outcome was all-cause mortality. Secondary outcome was ESRD incidence. Results: Of 103,363 patients 4,192 had pre-existing CKD; 1389 had ESRD; 5273 developed AKI and 998 CKD patients developed AoC. One-year mortality was greatest in AoC patients (54 %) followed by AKI (48.7 %), CKD (47.6 %) and ESRD (40.3 %) (P < 0.001). Five-year mortality was highest for the CKD and AoC groups (71.3 % and 68.2 %, respectively) followed by AKI (61.8 %) and ESRD (62.9 %) (P < 0.001). ESRD incidence was greatest in the AoC and CKD groups (adjusted incidence rate ratio (IRR) 259 (95 % confidence interval (CI) 156.9–429.1) and 96.4, (95 % CI 59.7–155.6) respectively) and elevated in AKI patients compared with controls (adjusted IRR 24 (95 % CI 3.9–42.0); P < 0.001). Risk factors independently associated with ESRD in 1-year survivors were, according to relative risk ratio, AoC (356; 95 % CI 69.9–1811), CKD (267; 95 % CI 55.1–1280), AKI (30; 95 % CI 5.98–154) and presence of elevated admission serum potassium (4.6; 95 % CI 1.30–16.40) (P < 0.001). Conclusions: Pre-ICU renal disease significantly increases risk of death compared with controls. Subjects with AoC disease had extreme risk of developing ESRD. All patients with CKD who survive critical care should receive a nephrology referral. Trial registration: Clinical trials registration number: NCT02424747 April 20th 2015.
- Open Access
- 6 May 2015
- Published by Springer Nature in Critical Care
- Vol. 19 (1) , 1-10
Evolution of chronic renal impairment and long-term mortality after de novo acute kidney injury in the critically ill; a Swedish multi-centre cohort study
Introduction: Acute Kidney Injury (AKI) is common in critical ill populations and its association with high short-term mortality is well established. However, long-term risks of death and renal dysfunction are poorly understood and few studies exclude patients with pre-existing renal disease, meaning outcome for de novo AKI has been difficult to elicit. We aimed to compare the long-term risk of Chronic Kidney Disease (CKD), End Stage Renal Disease (ESRD) and mortality in critically ill patients with and without severe de novo AKI.Method: This cohort study was conducted between 2005 and 2011 in Swedish intensive care units (ICU). Data from 130134 adult patients listed on the Swedish intensive care register-database was linked with other national registries. Patients with pre-existing CKD (4192) and ESRD (1389) were excluded, as were cases (26771) with incomplete data. Patients were classified according to AKI exposure during ICU admission. Outcome in the de novo AKI group was compared to the non-exposed (no-AKI) intensive care control group. Primary outcome was all-cause mortality. Follow-up ranged from one to seven years (median 2.1 years). Secondary outcomes were incidence of CKD and ESRD and median follow-up was 1.3 years.Results: Of 97 782 patients, 5273 (5.4%) had de novo AKI. These patients had significantly higher crude mortality at one (48.4% vs. 24.6%) and five years (61.8% vs. 39.1%) compared to the control group. The first 30% of deaths in AKI patients occurred within 11 days of ICU admission whilst the 30-centile in the no-AKI group died by 748 days. CKD was significantly more common in AKI survivors at one year (6.0% vs. 0.44%) than in no-AKI group (adjusted incidence rate ratio (IRR) 7.6). AKI patients also had significantly higher rates of ESRD at one (2.0% vs. 0.08%) and at five years (3.9% vs. 0.3%) than those in the comparison group (adjusted IRR 22.5).Conclusion: This large cohort study demonstrated that de novo AKI is associated with increased short and long-term risk of death. AKI is independently associated with increased risk of CKD and ESRD as compared to an ICU control population. Severe de novo AKI survivors should be routinely followed-up and their renal function monitored.
- 6 May 2015
- Published by Springer Nature in Critical Care
- Vol. 19 (1) , 1-10
Open AccessEvolution of chronic renal impairment and long-term mortality after de novo acute kidney injury in the critically ill; a Swedish multi-centre cohort study
Introduction: Acute Kidney Injury (AKI) is common in critical ill populations and its association with high short-term mortality is well established. However, long-term risks of death and renal dysfunction are poorly understood and few studies exclude patients with pre-existing renal disease, meaning outcome for de novo AKI has been difficult to elicit. We aimed to compare the long-term risk of Chronic Kidney Disease (CKD), End Stage Renal Disease (ESRD) and mortality in critically ill patients with and without severe de novo AKI.Method: This cohort study was conducted between 2005 and 2011 in Swedish intensive care units (ICU). Data from 130134 adult patients listed on the Swedish intensive care register-database was linked with other national registries. Patients with pre-existing CKD (4192) and ESRD (1389) were excluded, as were cases (26771) with incomplete data. Patients were classified according to AKI exposure during ICU admission. Outcome in the de novo AKI group was compared to the non-exposed (no-AKI) intensive care control group. Primary outcome was all-cause mortality. Follow-up ranged from one to seven years (median 2.1 years). Secondary outcomes were incidence of CKD and ESRD and median follow-up was 1.3 years.Results: Of 97 782 patients, 5273 (5.4%) had de novo AKI. These patients had significantly higher crude mortality at one (48.4% vs. 24.6%) and five years (61.8% vs. 39.1%) compared to the control group. The first 30% of deaths in AKI patients occurred within 11 days of ICU admission whilst the 30-centile in the no-AKI group died by 748 days. CKD was significantly more common in AKI survivors at one year (6.0% vs. 0.44%) than in no-AKI group (adjusted incidence rate ratio (IRR) 7.6). AKI patients also had significantly higher rates of ESRD at one (2.0% vs. 0.08%) and at five years (3.9% vs. 0.3%) than those in the comparison group (adjusted IRR 22.5).Conclusion: This large cohort study demonstrated that de novo AKI is associated with increased short and long-term risk of death. AKI is independently associated with increased risk of CKD and ESRD as compared to an ICU control population. Severe de novo AKI survivors should be routinely followed-up and their renal function monitored.
- 19 October 2011
- Published by Wiley in Acta Anaesthesiologica Scandinavica
- Vol. 56 (2) , 138-146
Long‐term outcome after acute renal replacement therapy: a narrative review
Background: Acute kidney injury (AKI) necessitating renal replacement therapy (RRT) is associated with high short‐term mortality, relatively little however is known of the long‐term outcome in these patients. This narrative review describes renal recovery, long‐term mortality, and quality of life in RRT patients with acute kidney injury.Methods: A literature search using the PubMed search engine from the year 2000 to present with the MeSH terms 1) acute kidney injury, renal replacement therapy, prognosis, and 2) acute kidney injury, quality of life, prognosis, was performed, including studies addressing long‐term outcome (over 60 days) in adults with AKI on RRT.Results: According to inclusion criteria, twenty two studies were eligible. Outcome varied depending on AKI aetiology, setting, co‐morbidity and pre‐morbid renal function. Five‐year‐survival was between 15% and 35%, with dialysis dependence in less than 10% of survivors. Renal recovery, even if incomplete occurred during the first year. Quality of life assessment amongst survivors indicated moderate physical impairment and reduced mental health scores. A majority of patients returned to employment and self‐sustainability and reported acceptable to good quality of life. Over 90% of patients indicated that they would undergo the same treatment again.Discussion and Conclusions: Early initiation of treatment and fine‐tuning of the RRT technique may improve outcome. Consensus regarding AKI definitions, renal function measurement and standardised follow‐up regimens are required. Further long‐term studies are needed.
- 19 October 2011
- Published by Wiley in Acta Anaesthesiologica Scandinavica
- Vol. 56 (2) , 138-146
Long‐term outcome after acute renal replacement therapy: a narrative review
Background: Acute kidney injury (AKI) necessitating renal replacement therapy (RRT) is associated with high short‐term mortality, relatively little however is known of the long‐term outcome in these patients. This narrative review describes renal recovery, long‐term mortality, and quality of life in RRT patients with acute kidney injury.Methods: A literature search using the PubMed search engine from the year 2000 to present with the MeSH terms 1) acute kidney injury, renal replacement therapy, prognosis, and 2) acute kidney injury, quality of life, prognosis, was performed, including studies addressing long‐term outcome (over 60 days) in adults with AKI on RRT.Results: According to inclusion criteria, twenty two studies were eligible. Outcome varied depending on AKI aetiology, setting, co‐morbidity and pre‐morbid renal function. Five‐year‐survival was between 15% and 35%, with dialysis dependence in less than 10% of survivors. Renal recovery, even if incomplete occurred during the first year. Quality of life assessment amongst survivors indicated moderate physical impairment and reduced mental health scores. A majority of patients returned to employment and self‐sustainability and reported acceptable to good quality of life. Over 90% of patients indicated that they would undergo the same treatment again.Discussion and Conclusions: Early initiation of treatment and fine‐tuning of the RRT technique may improve outcome. Consensus regarding AKI definitions, renal function measurement and standardised follow‐up regimens are required. Further long‐term studies are needed.